MCID: NRV006
MIFTS: 60

Nervous System Cancer

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Nervous System Cancer

MalaCards integrated aliases for Nervous System Cancer:

Name: Nervous System Cancer 12 15
Neuroepithelial, Perineurial, and Schwann Cell Neoplasm 73
Malignant Neoplasm of Nervous System 12
Neoplasm of the Nervous System 29
Tumor of the Nervous System 12
Neoplasm of Nervous System 12
Nervous System Neoplasms 73
Nervous System Neoplasm 12
Neoplasms, Nerve Tissue 44
Nervous System--Cancer 73
Nervous System Tumor 55
Neural Neoplasm 12
Neural Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3093
ICD9CM 35 192 192.9
MeSH 44 D009380
NCIt 50 C35562
SNOMED-CT 68 188306000

Summaries for Nervous System Cancer

Disease Ontology : 12 An organ system cancer located in the nervous system that affects the central or peripheral nervous system.

MalaCards based summary : Nervous System Cancer, also known as neuroepithelial, perineurial, and schwann cell neoplasm, is related to ependymoma and meningioma, familial. An important gene associated with Nervous System Cancer is CDKN2B-AS1 (CDKN2B Antisense RNA 1
A large germline deletion (403231 bp) encompassing the INK4/ARF locus and the ANRIL lncRNA has been associated with hereditary cutaneous malignant melanoma (CMM) and neural system tumors (NST) syndrome.
Dysfunction Pattern: Mutation), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Hydrocortisone and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include the nervous system, brain and pituitary, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Nervous System Cancer

Diseases related to Nervous System Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 166)
# Related Disease Score Top Affiliating Genes
1 ependymoma 33.3 ENO2 NF2 RB1
2 meningioma, familial 32.7 CDKN2B NF1 NF2 TP53
3 brain cancer 32.1 CASP3 ENO2 MYCN NF2 SHH TP53
4 ewing sarcoma 31.9 CASP3 CCND1 CDKN2A ENO2 MYC MYCN
5 sensory system cancer 31.7 CCND1 CDK2 CDK4 CDKN2A MYC RB1
6 peripheral nervous system neoplasm 31.6 BACE1 CASP3 ENO2 MYC MYCN NF1
7 neuroma 31.0 ENO2 NF1 NF2
8 neuroblastoma 30.4 BACE1 CASP3 ENO2 MYC MYCN TP53
9 medulloblastoma 29.8 CASP3 CCND1 CDKN2B CDKN2B-AS1 ENO2 MYC
10 olfactory neural tumor 12.0
11 non-hereditary retinoblastoma 11.2 MYCN RB1
12 vulvar adenocarcinoma 11.2 RB1 TP53
13 gliofibroma 11.2 NF1 TP53
14 plexiform neurofibroma 11.2 CDKN2B-AS1 NF1 NF2
15 ring chromosome 7 11.2 CDK4 TP53
16 neurofibromatosis, familial spinal 11.2 NF1 NF2
17 brain stem astrocytic neoplasm 11.2 CDKN2A TP53
18 bilateral retinoblastoma 11.1 MYCN RB1 RBL1
19 cerebral convexity meningioma 11.1 NF2 TP53
20 amyloid tumor 11.1 NF1 NF2 TUBB3
21 short-rib thoracic dysplasia 4 with or without polydactyly 11.1 CASP3 TP53
22 plexiform schwannoma 11.1 ENO2 NF1 NF2
23 small cell sarcoma 11.1 CDK4 NF2 TP53
24 thyroid lymphoma 11.1 CDKN2A CDKN2B TP53
25 scrotal carcinoma 11.1 CDKN2A CDKN2B TP53
26 breast papillomatosis 11.1 CCND1 CDKN2A
27 melanoma-pancreatic cancer syndrome 11.1 CDKN2A CDKN2B-AS1
28 spinal meningioma 11.1 ENO2 NF1 NF2
29 spinal canal and spinal cord meningioma 11.1 ENO2 NF1 NF2
30 neurofibromatosis, type iv, of riccardi 11.1 CDKN2B-AS1 NF1 NF2
31 lung meningioma 11.1 ENO2 NF2
32 periosteal chondrosarcoma 11.1 CDK4 CDKN2A RB1
33 oral leukoplakia 11.1 CCND1 CDKN2A TP53
34 clear cell ependymoma 11.1 ENO2 NF2 TP53
35 optic nerve glioma 11.1 ENO2 NF1 TP53
36 primary effusion lymphoma 11.1 CASP3 CDK2 MYC
37 neurofibroma 11.1 CDKN2A NF1 NF2
38 neurilemmoma 11.1 ENO2 NF1 NF2
39 atypical neurofibroma 11.1 CDKN2A CDKN2B NF1 NF2
40 autosomal genetic disease 11.1 NF1 NF2 TP53
41 deafness, autosomal recessive 74 11.1 BACE1 CASP3
42 ischemic fasciitis 11.1 CCND1 CDK4 CDKN2A
43 cerebellum cancer 11.1 ENO2 SHH TP53
44 askin's tumor 11.1 ENO2 MYC MYCN
45 meningeal melanomatosis 11.1 CDKN2A ENO2 TP53
46 liver angiosarcoma 11.1 CDK4 ENO2 TP53
47 adrenal neuroblastoma 11.0 ENO2 MYCN
48 meningothelial meningioma 11.0 ENO2 NF2
49 megaesophagus 11.0 CDKN2A MYC TP53
50 cellular schwannoma 11.0 CDKN2A NF1 NF2 TP53

Graphical network of the top 20 diseases related to Nervous System Cancer:



Diseases related to Nervous System Cancer

Symptoms & Phenotypes for Nervous System Cancer

GenomeRNAi Phenotypes related to Nervous System Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 10.13 MYC CDKN2A
2 Decreased viability GR00221-A-2 10.13 CDK2
3 Decreased viability GR00221-A-3 10.13 MYC NF2 SHH CDK2 CDKN2A
4 Decreased viability GR00221-A-4 10.13 CDKN2A
5 Decreased viability GR00301-A 10.13 CDK2
6 Decreased viability GR00402-S-2 10.13 MYC NF2 CDK2 SHH CDKN2A
7 Decreased viability in esophageal squamous lineage GR00235-A 9.85 CDKN2A MYCN BCHE NUMBL CCND1 RB1
8 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.73 CASP3 RB1 TP53 CDK2 CDKN2A
9 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.73 MYC CASP3 CCND1 RB1 TP53 CDK2
10 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.02 ENO2 MYCN RBL1 CDK2 CDK4

MGI Mouse Phenotypes related to Nervous System Cancer:

46 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.55 RBL1 RB1 SHH TUBB3 TP53 CDK2
2 behavior/neurological MP:0005386 10.51 RBL1 RB1 TP53 SHH CDKN2A CDK4
3 growth/size/body region MP:0005378 10.49 RBL1 RB1 TP53 SHH CDK2 CDKN2A
4 homeostasis/metabolism MP:0005376 10.47 RBL1 RB1 TP53 SHH CDK4 CDK2
5 mortality/aging MP:0010768 10.46 RBL1 RB1 TP53 SHH TUBB3 CDK2
6 cardiovascular system MP:0005385 10.41 RBL1 RB1 TP53 SHH CDK4 CDK2
7 endocrine/exocrine gland MP:0005379 10.41 RBL1 RB1 TP53 SHH CDK2 CDKN2A
8 hematopoietic system MP:0005397 10.39 NUMBL RBL1 RB1 TP53 CDK4 CDK2
9 integument MP:0010771 10.39 RBL1 RB1 SHH TP53 CDK2 CDKN2A
10 embryo MP:0005380 10.38 RBL1 RB1 TP53 SHH CDK2 CDKN2A
11 immune system MP:0005387 10.37 RBL1 RB1 TP53 SHH CDK4 CDK2
12 craniofacial MP:0005382 10.36 RBL1 RB1 TP53 SHH CCND1 CASP3
13 nervous system MP:0003631 10.36 RBL1 RB1 TP53 SHH TUBB3 CDKN2A
14 digestive/alimentary MP:0005381 10.35 RBL1 RB1 TP53 SHH CDKN2A CDK4
15 muscle MP:0005369 10.27 RBL1 RB1 TP53 SHH CDK2 CDKN2A
16 liver/biliary system MP:0005370 10.26 RBL1 RB1 TP53 SHH CDK2 CDKN2A
17 neoplasm MP:0002006 10.26 RBL1 RB1 SHH TP53 CDKN2A CDK4
18 hearing/vestibular/ear MP:0005377 10.24 NUMBL RBL1 RB1 TP53 SHH CASP3
19 normal MP:0002873 10.14 NUMBL RBL1 RB1 TP53 SHH CDK4
20 no phenotypic analysis MP:0003012 10.13 RBL1 RB1 TP53 SHH CDKN2A BACE1
21 reproductive system MP:0005389 10.13 RBL1 RB1 SHH TP53 CDKN2A CDK4
22 limbs/digits/tail MP:0005371 10.08 RB1 RBL1 TP53 SHH MYC NF1
23 renal/urinary system MP:0005367 10.02 RBL1 RB1 TP53 SHH CDK4 CASP3
24 respiratory system MP:0005388 9.93 RBL1 RB1 TP53 SHH TUBB3 CDKN2A
25 pigmentation MP:0001186 9.91 RB1 TP53 CDK4 CDKN2A CASP3 MYC
26 skeleton MP:0005390 9.7 RB1 RBL1 TP53 SHH CDKN2A CCND1
27 vision/eye MP:0005391 9.4 RBL1 RB1 TP53 SHH CDK2 CDKN2A

Drugs & Therapeutics for Nervous System Cancer

Drugs for Nervous System Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 685)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-23-7 5754
2
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
3
Dacarbazine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 4342-03-4 5351166
4
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85622-93-1 5394
5
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
6
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
7
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 113775-47-6 68602 5311068
8
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 28523-86-6 5206
9
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 2078-54-8 4943
10
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable 22916-47-8 4189
11
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83150-76-9 383414 6400441
12
Menthol Approved Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1 2216-51-5 16666
13
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
14
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 2180-92-9, 38396-39-3 2474
15
Thrombin Approved, Investigational Phase 4
16
Remifentanil Approved Phase 4,Phase 3,Not Applicable 132875-61-7 60815
17
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
18
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
19
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
20
Ibuprofen Approved Phase 4 15687-27-1 3672
21
Morphine Approved, Investigational Phase 4,Phase 2,Not Applicable 57-27-2 5288826
22
Oxycodone Approved, Illicit, Investigational Phase 4,Not Applicable 76-42-6 5284603
23
Clevidipine Approved, Investigational Phase 4 167221-71-8
24
Hydralazine Approved Phase 4 86-54-4 3637
25
Labetalol Approved Phase 4 36894-69-6 3869
26
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
27
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 113-45-1 4158
28 Piracetam Approved, Investigational Phase 4,Phase 2,Not Applicable 7491-74-9
29
Mitoxantrone Approved, Investigational Phase 4,Phase 1 65271-80-9 4212
30
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
31
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
32
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
33
Cefazolin Approved Phase 4 25953-19-9 656510 33255
34
Cefdinir Approved Phase 4 91832-40-5 6915944
35
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
36
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
37
Sulfamethoxazole Approved Phase 4,Phase 1 723-46-6 5329
38
Trimethoprim Approved, Vet_approved Phase 4,Phase 1 738-70-5 5578
39
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
40
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
41
Glutamic Acid Approved, Nutraceutical Phase 4,Not Applicable 56-86-0 33032
42
Butyric Acid Experimental, Investigational Phase 4,Phase 2,Not Applicable 107-92-6 264
43 Etiracetam Investigational Phase 4,Phase 1,Phase 2,Not Applicable 33996-58-6
44
Lactitol Investigational Phase 4,Phase 2 585-86-4 3871
45 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Cortisol succinate Phase 4,Phase 2,Not Applicable
49 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1823)
# Name Status NCT ID Phase Drugs
1 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
2 Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System Completed NCT02343081 Phase 4 Temozolomide;Temozolomide
3 Validation of 3 Dimensional Laparoscopic System in Disral Pancreatectomy and Splenectomy Completed NCT02757690 Phase 4
4 DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor Completed NCT00029523 Phase 4 Intrathecal (injected into the spinal fluid) DepoCyt;Intrathecal methotrexate;Intrathecal cytarabine (also known as ara-C)
5 Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy Completed NCT02810899 Phase 4 dexmedetomidine;normal saline
6 Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants Completed NCT02708056 Phase 4 Sugammadex
7 Scalp Nerve Block and Opioid Consumption in Brain Surgery Completed NCT02057367 Phase 4 Scalp block with 0.5% plain Marcaine;Scalp block with 0.9% normal saline
8 Phase IV Bioseal Study in Brain Tumor Surgery Completed NCT02034799 Phase 4
9 Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors Completed NCT02034708 Phase 4 Dotarem®;Gadovist®/Gadavist®
10 Remifentanil Infusion Alone During the Closure Period for Early Emergence Following Craniotomy Completed NCT02593942 Phase 4 Remifentanil;Propofol
11 Multihance at 3 Tesla in Brain Tumors Completed NCT00395863 Phase 4 Multihance;Arm 2 - Magnevist
12 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
13 Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
14 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
15 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
16 Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors Completed NCT00075166 Phase 4
17 A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients Completed NCT00952081 Phase 4 Clevidipine
18 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
19 Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery Completed NCT00571155 Phase 4 levetiracetam
20 NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate Completed NCT00169611 Phase 4 methylphenidate
21 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
22 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
23 Single Dose Tramadol Effect on Extubation Response and Quality of Emergence Post-supratentorial Intracranial Surgery Recruiting NCT02964416 Phase 4 Injection Tramadol
24 Dexmedetomidine and Propofol for Pediatric MRI Sedation Recruiting NCT03513757 Phase 4 propofol;Dexmedetomidine
25 Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach Recruiting NCT03132259 Phase 4 high dose dexmedethomidine;low dose dexmedethomidine
26 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
27 Cavernous Sinus Dissection and Bleeding in Meningiomas Recruiting NCT02863484 Phase 4
28 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Recruiting NCT02478346 Phase 4 Fluorescein Sodium
29 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Recruiting NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
30 1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients Recruiting NCT02334722 Phase 4 Levetiracetam extended release
31 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
32 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Recruiting NCT02379754 Phase 4 Gentamicins
33 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
34 Comparison of Efficacy and Safety of the Postoperative Analgesia Methods Not yet recruiting NCT02929147 Phase 4 Morphine;Dexketoprofen;Placebo
35 Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. Not yet recruiting NCT03190122 Phase 4
36 Different Dose of Methotrexate for the Treatment of Meningeal Carcinomatosis Not yet recruiting NCT02590510 Phase 4 methotrexate
37 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Terminated NCT02028325 Phase 4 Fluorescein Sodium
38 Treatment of Resectable Malignant Brain Tumors Terminated NCT00415467 Phase 4
39 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
40 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
41 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
42 Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
43 Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma Unknown status NCT00053872 Phase 3 cisplatin;lomustine;vincristine sulfate
44 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
45 Prevention of Imminent Paralysis Following Spinal Cord Trauma or Ischemia by Minocycline: A Multi-center Study in Israel With IDF Primary Care Involvement Unknown status NCT01813240 Phase 2, Phase 3 Minocycline;placebo
46 Efficacy of Tranexamic Acid in Brain Tumor Resections Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
47 Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children Unknown status NCT00749723 Phase 2, Phase 3 carboplatin;etoposide;temozolomide;thiotepa, carboplatin, etoposide;temozolomide, thiotepa;etoposide;trofosfamide/etoposide
48 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
49 Local Radiotherapy Following Complete Resection of a Brain Metastasis Unknown status NCT02729558 Phase 3
50 Stereotactic Radiotherapy of Resection Cavity For Single Brain Metastasis Versus Whole-Brain Radiotherapy After Resection Unknown status NCT01535209 Phase 3

Search NIH Clinical Center for Nervous System Cancer

Cochrane evidence based reviews: neoplasms, nerve tissue

Genetic Tests for Nervous System Cancer

Genetic tests related to Nervous System Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of the Nervous System 29

Anatomical Context for Nervous System Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Nervous System Cancer:

19
The Nervous System

MalaCards organs/tissues related to Nervous System Cancer:

41
Brain, Pituitary, Lung, Bone, Bone Marrow, T Cells, Spinal Cord

Publications for Nervous System Cancer

Articles related to Nervous System Cancer:

(show all 25)
# Title Authors Year
1
Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: protocol for a scoping review. ( 29374660 )
2018
2
The Complex Diagnostic Challenge in Children With Non-Central Nervous System Cancer and Cerebellar Mutism. ( 28497710 )
2017
3
Meta-Analysis of the Effects of Neuropsychological Interventions on Cognitive Function in Non-Central Nervous System Cancer Survivors. ( 27151596 )
2016
4
Stat Bite Number of New Brain and Other Nervous System Cancer Cases By Race/Ethnicity & Sex (2008-2012). ( 26538626 )
2015
5
Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. ( 25483452 )
2015
6
Five-year relative survival rate of brain and other nervous system cancer in the USA, Europe and Japan. ( 25717112 )
2015
7
Brain and central nervous system cancer incidence in navarre (Spain), 1973-2008 and projections for 2014. ( 25561983 )
2015
8
Identification of miRNAs as potential new biomarkers for nervous system cancer. ( 25139093 )
2014
9
Vocational identity, positive affect, and career thoughts in a group of young adult central nervous system cancer survivors. ( 25035908 )
2014
10
Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients. ( 23661397 )
2013
11
Medulloblastoma and Brucellosis - Molecular Evidence of Brucella sp in Association with Central Nervous System Cancer. ( 21475718 )
2011
12
Comparison of time trends in brain and central nervous system cancer mortality (1990-2006) between countries based on the WHO mortality database. ( 21273379 )
2011
13
Pain in children with central nervous system cancer: a review of the literature. ( 20591796 )
2010
14
Long-term health experience of jet engine manufacturing workers: IV. A comparison of central nervous system cancer ascertainment using mortality and incidence data. ( 20816315 )
2010
15
School-aged children after the end of successful treatment of non-central nervous system cancer: longitudinal assessment of health-related quality of life, anxiety and coping. ( 19594611 )
2009
16
Induction of cytotoxicity, apoptosis and cell cycle arrest by 1-t-butyl carbamoyl, 7-methyl-indole-3-ethyl isothiocyanate (NB7M) in nervous system cancer cells. ( 19920894 )
2009
17
Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. ( 18415683 )
2008
18
Comparison of time trends in brain central nervous system cancer incidence (1973-97) in East Asia, Europe and USA, from Cancer Incidence in Five Continents Vols IV-VIII. ( 18772173 )
2008
19
Molecular predictors of human nervous system cancer responsiveness to enediyne chemotherapy. ( 18338171 )
2008
20
Cytotoxicity and oncostatic activity of the thiazolidinedione derivative CGP 52608 on central nervous system cancer cells. ( 15194216 )
2004
21
Exploitation of immune mechanisms in the treatment of central nervous system cancer. ( 10914414 )
2000
22
Nervous system cancer mortality in an industrialized area of Brazil 1980-1993. ( 10920400 )
2000
23
Risk of nervous system cancer among workers exposed to lead. ( 8673517 )
1996
24
Human malignant astrocytoma xenografts migrate in rat brain: a model for central nervous system cancer research. ( 2651679 )
1989
25
Brain and central nervous system cancer mortality in U. S. rubber workers. ( 6953785 )
1982

Variations for Nervous System Cancer

Expression for Nervous System Cancer

Search GEO for disease gene expression data for Nervous System Cancer.

Pathways for Nervous System Cancer

Pathways related to Nervous System Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.94 CASP3 CCND1 CDK2 CDK4 CDKN2A CDKN2B
2
Show member pathways
13.76 CCND1 CDK2 CDK4 CDKN2A CDKN2B MYC
3
Show member pathways
13.51 CCND1 CDK2 CDK4 CDKN2A CDKN2B MYC
4
Show member pathways
13.17 CDK2 CDK4 CDKN2A CDKN2B RB1 TP53
5
Show member pathways
13.08 CASP3 CCND1 CDK2 CDK4 MYC RB1
6
Show member pathways
13.06 CCND1 CDK2 CDK4 CDKN2A CDKN2B RB1
7
Show member pathways
12.98 CASP3 CCND1 CDK2 CDK4 CDKN2A MYC
8 12.88 CASP3 CCND1 CDK2 CDK4 CDKN2A CDKN2B
9
Show member pathways
12.87 CCND1 CDK2 CDK4 CDKN2A CDKN2B NF1
10
Show member pathways
12.86 CCND1 CDK2 CDK4 CDKN2A CDKN2B MYC
11
Show member pathways
12.82 CASP3 CCND1 CDK2 CDK4 TP53
12
Show member pathways
12.8 CASP3 CCND1 CDK2 CDK4 MYC RB1
13 12.69 BACE1 ENO2 MYCN NF1 NF2 TUBB3
14
Show member pathways
12.68 CASP3 CCND1 CDK2 CDK4 MYC RB1
15 12.62 CCND1 CDK2 CDK4 CDKN2A RB1 TP53
16
Show member pathways
12.6 CASP3 CCND1 MYC RB1 TP53
17
Show member pathways
12.6 CCND1 CDK2 CDK4 CDKN2A CDKN2B MYC
18 12.58 CASP3 CCND1 CDKN2A MYC TP53
19 12.53 CCND1 CDK4 CDKN2A CDKN2B MYC RB1
20
Show member pathways
12.48 CASP3 CCND1 CDK2 CDK4 CDKN2A MYC
21
Show member pathways
12.45 CCND1 CDK2 CDK4 CDKN2A CDKN2B RB1
22
Show member pathways
12.44 CCND1 CDK2 CDK4 RB1
23 12.4 CASP3 CCND1 MYC SHH TP53
24
Show member pathways
12.38 CASP3 CCND1 CDK2 CDK4 RB1 TP53
25 12.38 CCND1 CDK2 CDK4 CDKN2A CDKN2B MYC
26
Show member pathways
12.34 CCND1 CDK2 CDK4 CDKN2A CDKN2B MYC
27 12.33 CDK2 MYC RB1 TP53
28 12.28 CASP3 CCND1 CDK2 CDK4 MYC TP53
29 12.28 CASP3 CCND1 CDK2 CDK4 CDKN2A CDKN2B
30 12.23 CASP3 CCND1 MYC TP53
31 12.19 CASP3 CCND1 CDK2 CDK4 MYC NF1
32
Show member pathways
12.18 CCND1 CDK4 MYC RB1
33 12.18 CCND1 CDKN2B MYC RBL1 TP53
34
Show member pathways
12.12 CCND1 CDK2 CDK4 NF1
35 12.1 CDK2 CDKN2A RB1 TP53
36
Show member pathways
12.1 CCND1 CDK2 CDK4 MYC RB1 RBL1
37 12.1 CASP3 CCND1 CDK2 CDK4 MYC RB1
38 12.07 CCND1 CDKN2A MYC TP53
39 11.98 CCND1 CDK2 CDK4 MYC RB1 TP53
40 11.9 CDK2 CDK4 CDKN2B MYC RBL1
41 11.86 CCND1 CDK4 CDKN2A MYC RB1 TP53
42 11.85 CDK2 MYC RB1 RBL1
43 11.84 CDKN2B MYC RBL1
44 11.82 CDK4 MYC TP53
45 11.82 CDK2 CDK4 MYC RB1
46 11.81 CCND1 CDK2 CDK4 CDKN2A CDKN2B MYC
47 11.77 CASP3 CDKN2A TP53
48
Show member pathways
11.77 CDK2 CDKN2A TP53
49 11.76 CCND1 CDKN2B MYC RBL1
50 11.73 CASP3 CCND1 CDK2 CDK4 CDKN2B MYC

GO Terms for Nervous System Cancer

Cellular components related to Nervous System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleolus GO:0005730 9.7 CDK4 CDKN2A MYC MYCN NF1 NF2
2 transcription factor complex GO:0005667 9.56 CDK2 CDK4 RB1 RBL1
3 chromatin GO:0000785 9.26 CDK4 MYCN RB1 RBL1
4 cyclin-dependent protein kinase holoenzyme complex GO:0000307 8.8 CCND1 CDK2 CDK4
5 nucleus GO:0005634 10.17 CASP3 CCND1 CDK2 CDK4 CDKN2A CDKN2B

Biological processes related to Nervous System Cancer according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.97 CDK4 NF1 NF2 SHH
2 regulation of gene expression GO:0010468 9.93 CDK2 CDK4 MYC NF1 SHH
3 negative regulation of gene expression GO:0010629 9.89 MYC MYCN RB1 RBL1 SHH
4 negative regulation of protein kinase activity GO:0006469 9.88 CDKN2A NF1 NF2 RB1
5 negative regulation of cell proliferation GO:0008285 9.87 BCHE CDKN2A CDKN2B NF1 NF2 RB1
6 regulation of mitotic cell cycle GO:0007346 9.86 MYC RB1 RBL1
7 cell cycle GO:0007049 9.86 CCND1 CDK2 CDK4 CDKN2A CDKN2B RB1
8 canonical Wnt signaling pathway GO:0060070 9.85 CCND1 MYC SHH
9 response to organic substance GO:0010033 9.85 CASP3 CCND1 CDK2 CDK4
10 response to glucocorticoid GO:0051384 9.83 BCHE CASP3 CCND1
11 cell cycle arrest GO:0007050 9.83 CDKN2A CDKN2B MYC RB1 TP53
12 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.82 CDKN2B RB1 RBL1
13 positive regulation of neuron apoptotic process GO:0043525 9.81 CASP3 NF1 TP53
14 positive regulation of cell cycle GO:0045787 9.8 CCND1 CDK4 MYC
15 negative regulation of fibroblast proliferation GO:0048147 9.76 MYC NF1 TP53
16 positive regulation of mesenchymal cell proliferation GO:0002053 9.73 MYC MYCN SHH
17 response to X-ray GO:0010165 9.69 CASP3 CCND1 TP53
18 ectoderm development GO:0007398 9.68 NF2 SHH
19 replicative senescence GO:0090399 9.68 CDKN2A TP53
20 negative regulation of astrocyte differentiation GO:0048712 9.67 MYCN NF1
21 re-entry into mitotic cell cycle GO:0000320 9.65 CCND1 MYC
22 regulation of protein localization to nucleus GO:1900180 9.65 NF2 SHH